Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06346054 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Molecular Assessment for Gastro-Esophageal Cancer

Study acronym: MAGEC
StatusRecruiting
PhaseNot applicable
SponsorKU Leuven
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv3
  2. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Jul 1, 2024 to Aug 1, 2024
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
KU Leuven
69 trials monitored
See all monitored trials
Gastric Cancer
1,278 trials monitored
See 63 trials at risk
Esophageal Cancer
1,049 trials monitored
See 54 trials at risk
The goal of this minimally invasive interventional study is to learn if oncometabolic biomarkers, detected in the exhaled breath and blood can identify early-stage gastro-oesophageal cancer in patient at risk for gastro-oesophageal cancer. The main questions this study aims to answer: Are oncometabolites proficient and reproducible enough to function as diagnostic biomarkers? Can these biomarkers identify early-stage gastro-esophageal cancer? Researchers will compare participants with gastro-oesophageal cancer to healthy controls and participants with Barrett's esophagus to detect meaningful differences between the groups. Participants will provide a breath and blood sample during their routine standard of care visits.
Trial Details
NCT Number NCT06346054
Lead Sponsor KU Leuven
Conditions
(from sponsor)		 Esophageal Cancer, Gastric Cancer, Barrett Esophagus
Related terms Barrett Esophagus, Esophageal Neoplasms, Neoplasms, Stomach Neoplasms
Enrollment 1,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov